The authors concluded that the evidence for the effectiveness of pharmacological and non-pharmacological interventions to relieve cough in adults with non-malignant respiratory conditions was limited. Many trials had conflicting results and were hindered by variable quality scores and small sample sizes. The authors' conclusion is likely to be reliable.
Study selection
Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) of pharmacological or non-pharmacological interventions (classified by the EU directive 2001/83/EEC and defined in the paper) administered in any clinical setting to adult patients with acute, subacute or chronic cough due to non-malignant respiratory and non-respiratory diseases with a high prevalence of cough were eligible for inclusion. The primary outcomes of interest were subjective measures of cough frequency, severity or distress using validated and reliable methods (such as visual analogue, numeric rating or categorical scales). Secondary outcomes of interest were objective improvement of cough, quality of life, side-effects and patient withdrawal from trials. Patients with upper respiratory tract infection and cough reflex sensitivity studies were excluded.
Most of the included studies were conducted in patients with asthma or chronic obstructive pulmonary disease (COPD). Studies were conducted worldwide (10 were in UK). Pharmacological treatments included a range of corticosteroids, leukotriene receptor antagonists, mast cell stabilisers, ipratropium bromide, neltenexine, iodinised glycerol, lidocaine, and codeine. Non-pharmacological treatments included biological targeted imagery, SMS text messaging, ayurverdic herbs and speech pathology training. Control groups included placebo, other active treatment or different regimen and standard care. Most studies did not include cough as the primary outcome and used unvalidated measurement methods.
Two reviewers selected the studies for inclusion. Disagreements were resolved by discussion.
Assessment of study quality
Study quality was assessed using the Jadad scale of randomisation, blinding and withdrawals/drop-outs. Scores could range from zero to a maximum 5 (highest quality).
One reviewer carried out the quality assessment and agreement on all studies was reached with a second reviewer. For consistency, a third reviewer checked a random sample of studies.
Data extraction
Data were extracted on the outcomes of interest. Numerous measures of effect were presented.
One reviewer extracted data. A second reviewer independently checked a sample of papers to reach agreement. For 
Methods of synthesis
A narrative synthesis was presented by disease type.
Results of the review
Seventy-five trials (11,738 participants, range eight to 5,887) were included in the review. Mean sample size was 156 (78 when the largest trial was excluded). Jadad scores were: seven trials scored 5, 17 scored 4, 24 scored 3, 19 scored 2 and eight scored 1. Fifty-six trials were double-blind.
Asthma (23 trials): All trials that evaluated steroids showed positive effects on cough outcomes, particularly beclomethasone (four trials) and budesonide (one trial). Mast cell stabilisers, notably disodium cromoglycate (one trial) and lodoxadine (one trial) were effective. Two trials found nedocromil sodium to be effective, but no significant improvements were reported in two large trials. Leukotriene receptor antagonists (two trials), and Th2 cytokine inhibitor (one trial) showed positive effects. Also effective were the ayurverdic herbs deriphylline (with salbutamol) (one trial) and ginger (one trial) and SMS text messaging (one trial). There was no significant difference in one trial of theophylline.
COPD (18 trials): Three trials of neltenexine and single trials of fenspiride, fluticasone, formoterol, oxtriphylline, highdose N-acetylcysteine (1,200μg) and the biological extract helicidine were effective. The largest trial in this analysis (5,887 participants) evaluated a smoking cessation programme that led to a significant decrease in cough symptoms. Treatment effects were non-significant in single trials of budesonide, codeine, nesosteine, and inhaled oxitropium bromide (in addition to theophylline).
Bronchitis (eight trials): Effective treatments were epinastine (one trial), ipratropium bromide compared with fenspiride (one trial), theophylline (one trial) and iodinised glycerol (two trials). Non-significant treatment effects were found for low-dose N-acetylcysteine (two trials) and budenoside (one trial).
